Strides Targets $200-400m From Generic Injectables In Mid-Term

Insulin Glargine, Lispro In Development

Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Growth
Strides Chalks Stelis' Growth Strategy • Source: Shutterstock

Strides Pharma Science Ltd. (formerly known as Strides Shasun Ltd.) has set a revenue target of $200-400m over the next two to four years for the injectables business housed under Stelis Biopharma Pvt Ltd., a company in which it is a majority shareholder.

In a presentation to investors on 5 December outlining its strategy to get to $800m in group sales over the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia